AGTC 701
Alternative Names: AGTC-701Latest Information Update: 29 Jun 2023
Price :
$50 *
At a glance
- Originator Applied Genetic Technologies Corporation
- Developer Beacon Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration
Most Recent Events
- 16 Mar 2022 Applied Genetic Technologies Corporation plans to submit IND application of AGTC 701 in Dry age-related macular degeneration in the first half of 2023
- 21 Feb 2022 Applied Genetic Technologies Corporation plans toxicology and biodistribution studies, in 2022
- 31 Dec 2021 Preclinical trials in Dry age-related macular degeneration in USA, prior to December 2021